Investor actively backing innovative startups and growth-stage companies across various industries and funding rounds.
Verified emails & LinkedIn for founders across this portfolio.
Myra Vision develops a treatment that allows maximum IOP reduction for patients with moderate to severe glaucoma.
MoonLake Immunotherapeutics is a clinical-stage biopharmaceuticals company.
Triveni Bio is a biotechnology company that develops antibody-based therapeutics for immunological and inflammatory diseases.
Enliven Therapeutics is a precision oncology company developing small molecule therapies to extend and improve patient lives.
Pharvaris is a clinical-stage biomedical company focused on bringing oral bradykinin B2-receptor antagonists to patients.
Artiva Biotherapeutics is a biotech company focused on developing and commercializing allogeneic natural killer (NK) cell therapies.
Cabaletta Bio has adapted clinically-validated and FDA-approved CAR T cell technology to target B cell-mediated autoimmune diseases.
ConnectRN is a tech-enabled network built to improve clinicians' lives through access to community, opportunity, and support.
CARGO Therapeutics develops an adoptive cell therapy to benefit patients from potentially curative treatment options.
Icosavax is focused on developing safe and effective vaccines against infectious diseases that address important unmet medical needs.
Quince Therapeutics is developing treatments for Alzheimer's and other degenerative disorders.
Antares is a biotechnology company focused on developing transformational,medicines targeting validated cancer and other serious diseases.
MOMA Therapeutics operates as a biotechnology company.
Valneva focuses on the development and commercialization of prophylactic vaccines for infectious diseases.
GH Research is a biopharmaceutical company developing novel therapies for the management of mental illness.
Oruka Therapeutics is advancing innovative biologics to redefine patient care standards in chronic skin diseases.
Climb Bio occurs when the immune system mistakenly attacks the body's tissues and can result in permanent organ damage or even death.
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Ventus Therapeutics develops small molecule drugs that target autoimmune diseases, inflammatory diseases, and cancer.
Terremoto Biosciences is a biotechnology company leveraging the power of lysine-based covalency to develop optimized medicines.
Attovia Therapeutics is a biologics platform specializing in biotherapeutics for immune-mediated diseases.
Spyre Therapeutics is a biotechnology business that is developing a strong pipeline of antibody therapies.
Korro Bio provides an efficient and selective method for RNA editing, leveraging natural processes common to all multi-cellular organisms.
Solid Biosciences is a life science company that conducts research for the treatment of Duchenne muscular dystrophy.
Cormorant Asset Management has invested in 209 companies tracked in our database. The portfolio spans multiple industries and funding stages, from seed-stage startups to late-stage companies.
Cormorant Asset Management's top investment sectors include Biotechnology, Health Care, Therapeutics, Medical, Pharmaceutical. The firm invests across 17 different industry categories.
Among tracked funding rounds, Oruka Therapeutics received $700.4M in a Post-IPO Equity round. Cormorant Asset Management's total known invested capital is $23.5B.
Cormorant Asset Management's average investment size is $137.2M across its portfolio of 209 companies.
Recent Cormorant Asset Management portfolio additions include Myra Vision, MoonLake Immunotherapeutics, Triveni Bio, Enliven Therapeutics, Pharvaris. These companies were founded in 2020 or later.